Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$33,695 Mln
Revenue (TTM)
$5,398 Mln
Net Profit (TTM)
$1,486 Mln
ROE
0.3 %
ROCE
22.3 %
P/E Ratio
22.8
P/B Ratio
5.3
Industry P/E
56.97
EV/EBITDA
15.8
Div. Yield
1 %
Debt to Equity
0.1
Book Value
$--
EPS
$10.1
Face value
--
Shares outstanding
145,678,401
CFO
$5,283.93 Mln
EBITDA
$8,240.34 Mln
Net Profit
$4,886.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ResMed (RMD)
| -5.4 | -10.9 | -7.3 | 1.4 | 3.2 | 3.5 | 15.1 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ResMed (RMD)
| 5.3 | 32.6 | -17.3 | -20.1 | 22.5 | 37.2 | 36.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ResMed (RMD)
|
227.9 | 33,694.9 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.8 | 5.3 |
| 108.5 | 187,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 158.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 | |
| 71.3 | 102,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 | |
| 191.5 | 132,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 82.6 | 47,515.3 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.2 | 4.8 | |
| 577.1 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 | |
| 477.7 | 167,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 345.8 | 128,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 464.7 | 172,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments,... Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. Read more
CEO & Chairman
Mr. Michael J. Farrell BE, MBA, SM
CEO & Chairman
Mr. Michael J. Farrell BE, MBA, SM
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ResMed Inc (RMD) is $227.88 (NYSE) as of 18-Mar-2026 16:00 EDT. ResMed Inc (RMD) has given a return of 3.24% in the last 3 years.
The P/E ratio of ResMed Inc (RMD) is 22.83 times as on 13-Mar-2026, a 60 discount to its peers’ median range of 56.97 times.
The P/B ratio of ResMed Inc (RMD) is 5.32 times as on 13-Mar-2026, a 76 premium to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
27.08
|
6.36
|
|
2024
|
27.66
|
5.81
|
|
2023
|
35.92
|
7.81
|
|
2022
|
39.54
|
9.17
|
|
2021
|
76.13
|
12.52
|
The 52-week high and low of ResMed Inc (RMD) are Rs 293.81 and Rs 199.92 as of 19-Mar-2026.
ResMed Inc (RMD) has a market capitalisation of $ 33,695 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in ResMed Inc (RMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-5.62
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.